As of Friday close, Intellia Therapeutics Inc.’s (NASDAQ:NTLA) stock was up $0.36, moving up 0.97 percent to $37.59. The average number of shares traded per day over the past five days has been 686,920 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.92 fall in that time frame. In the last twenty days, the average volume was 738,310, while in the previous 50 days, it was 900,162.
Since last month, NTLA stock retreated -13.15%. Shares of the company fell to $36.53 on 08/18/23, the lowest level in the past month. A 52-week high of $69.28 was reached on 06/14/23 after having rallying from a 52-week low of $32.44. Since the beginning of this year, NTLA’s stock price has risen by 7.74% or $2.70, and marked a new high 12 times. However, the stock has declined by -45.74% since its 52-week high.
NTLA stock investors should be aware that Intellia Therapeutics Inc. (NTLA) stock had its last reported insider trading activity 19 days ago on Jul 31. Bhanji Muna, the Director of the company, disposed of 265 shares for $42.33 on Jul 31. It resulted in a $11,217 divestment by the insider. Bhanji Muna sold 1,867 shares at an average price of $39.30 on Jul 06. The insider now owns 12,526 shares following the transaction. On Jul 03, EVP, Chief Technical Officer Clark Eliana sold 360 shares at $40.51 apiece. The transaction was valued at $14,584.
Valuation Metrics
The stock’s beta is 1.84. Besides these, the trailing price-to-sales (P/S) ratio of 62.82, the price-to-book (PB) ratio of 3.00.
Financial Health
In the three months ended June 29, Intellia Therapeutics Inc.’s quick ratio stood at 9.40, while its current ratio was 9.40, showing that the company is able to pay off its debt. Based on annual data, NTLA earned $510.29 million in gross profit and brought in $52.12 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -37.10%. Return on equity (ROE) for the past 12 months was -41.60%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. NTLA’s revenue fell -3.24% to $12.61 million during the quarter, while net income inched up to $13.59 million. While analysts expected Intellia Therapeutics Inc. to report -$1.32 quarterly earnings, the actual figure was -$1.4 per share, beating the consensus estimate by -6.10%. During the quarter, the company generated -$130.16 million in EBITDA. The liabilities of Intellia Therapeutics Inc. were 218.35 million at the end of its most recent quarter ended June 29, and its total debt was $122.33 million. The value of shareholders’ equity is $88.49 million.
Technical Picture
This quick technical analysis looks at Intellia Therapeutics Inc.’s (NTLA) price momentum. With a historical volatility rate of 22.81%, the RSI 9-day stood at 30.57% on 18 August.
With respect to its five-day moving average, the current Intellia Therapeutics Inc. price is down by -4.86% percent or -$1.92. At present, NTLA shares trade -13.33% below its 20-day simple moving average and +1.18% percent above its 100-day simple moving average. However, the stock is currently trading approximately -13.51% below its SMA50 and -28.78% below its SMA200.
Stochastic coefficient K was 8.70% and Stochastic coefficient D was 8.93%, while ATR was 1.46. Given the Stochastic reading of 21.12% for the 14-day period, the RSI (14) reading has been calculated as 35.66%. As of today, the MACD Oscillator reading stands at -1.30, while the 14-day reading stands at -1.60.
Analyst Ratings
Canaccord Genuity launched its rating on Intellia Therapeutics Inc. (NASDAQ: NTLA) to a Buy in a note to investors on April 13, 2023. Intellia Therapeutics Inc. (NTLA) has been rated Buy by analysts. According to 0 brokerage firms, NTLA is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 3 analysts rate Intellia Therapeutics Inc. stock as buy, with 22 recommending it as overweight.
With a median target price of $80.00, the current consensus forecast for the stock is $38.00 – $157.00. Based on these forecasts, analysts predict Intellia Therapeutics Inc. (NTLA) will achieve an average price target of $83.52.
